Cargando…
Pharmacogenetic testing among patients with depression in a US managed care population
Actionable drug–gene pairs relevant to depression treatment include CYP2D6 and CYP2C19 with specific antidepressants. While clinical use of pharmacogenetic testing is growing, little is known about pharmacogenetic testing for depression treatment in managed care. We determined the incidence of singl...
Autores principales: | Anderson, Heather D., Thant, Thida M., Kao, David P., Crooks, Kristy R., Mendola, Nicholas D., Aquilante, Christina L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283740/ https://www.ncbi.nlm.nih.gov/pubmed/35385214 http://dx.doi.org/10.1111/cts.13279 |
Ejemplares similares
-
The landscape of pharmacogenetic testing in a US managed care population
por: Anderson, Heather D., et al.
Publicado: (2020) -
Survey of U.S. Public Attitudes Towards Pharmacogenetic Testing
por: Haga, Susanne B., et al.
Publicado: (2011) -
The Utility of Pharmacogenetics Testing in Psychiatric Populations
por: Jürgens, Gesche
Publicado: (2021) -
Multi-site investigation of strategies for the clinical implementation of preemptive pharmacogenetic testing
por: Duarte, Julio D., et al.
Publicado: (2021) -
Exploring Pharmacogenetic Testing for Hypertension Management in China
por: Zhao, Zhenping, et al.
Publicado: (2023)